Taysha Gene Therapies CEO RA Session's 2022 pay falls 57% to $2M
Taysha Gene Therapies reports 2022 executive compensation
By ExecPay News
Published: May 8, 2023
Taysha Gene Therapies reported fiscal year 2022 executive compensation information on May 8, 2023.
In 2022, four executives at Taysha Gene Therapies received on average a compensation package of $1.6M, a 44% decrease compared to previous year.
Average pay of disclosed executives at Taysha Gene Therapies
RA Session II, Chief Executive Officer, received $2M in total, which decreased by 57% compared to 2021. 59% of Session's compensation, or $1.2M, was in option awards. Session also received $271K in bonus, $538K in salary, as well as $173 in other compensation.
Sean Nolan, Chief Executive Officer, received a compensation package of $1.9M. 95% of the compensation package, or $1.8M, was in option awards.
Sukumar Nagendran, President and Head of Research and Development, earned $1.4M in 2022.
Kamran Alam, Chief Financial Officer, received $1.2M in 2022, which decreases by 34% compared to 2021.
Related executives
You may also like
Source: SEC filing on May 8, 2023.